Whole genome sequencing (WGS) is the process of determining the complete DNA sequence of an organism's genome at a single time. It reads all 3 billion base pairs in the human genome, including coding and non-coding regions, providing a complete view of genetic variation.
Unlike targeted tests that examine only specific genes or regions, WGS captures every part of the genome. This includes variants linked to inherited disorders, cancer mutations, drug response markers, and rare genetic conditions. It is used in clinical diagnostics, research, and personalized medicine.
WGS is distinct from whole exome sequencing (WES), which focuses only on protein-coding regions-about 1% of the genome. While WES is faster and cheaper, it misses regulatory elements and structural variants outside exons. WGS detects both known and novel variants across the entire genome.
WGS begins with extracting DNA from blood, saliva, or tissue samples. The sample is fragmented into small pieces, then amplified using polymerase chain reaction (PCR). These fragments are sequenced using high-throughput platforms like Illumina's NovaSeq or Oxford Nanopore's MinION.
Sequencing generates billions of short reads-fragments of DNA sequence. Bioinformatics tools align these reads to a reference human genome (GRCh38), identifying differences such as single nucleotide variants (SNVs), insertions, deletions, copy number changes, and structural rearrangements.
A key step is variant calling, where software compares each individual's sequence to the reference. Variants are filtered based on frequency in population databases like gnomAD, pathogenicity predictions (e.g., SIFT, PolyPhen), and inheritance patterns. Results are reported with clinical significance classifications (pathogenic, likely pathogenic, benign, etc.) according to ACMG guidelines.
WGS is applied across medical, research, and forensic domains. Clinical uses include diagnosing rare genetic diseases, identifying cancer driver mutations, and guiding pharmacogenomic therapy.
| Application | Use Case | Example |
|---|---|---|
| Clinical Diagnosis | Identifying undiagnosed genetic disorders | Diagnosing a child with developmental delay and seizures; WGS reveals a de novo mutation in SCN1A, confirming Dravet syndrome. |
| Oncology | Detecting tumor-specific mutations | Identifying BRAF V600E mutation in melanoma to select targeted therapy (vemurafenib). |
| Prenatal Screening | Assessing fetal risk from maternal blood | Non-invasive prenatal testing (NIPT) using WGS to detect trisomy 21 with 99.9% sensitivity. |
| Research | Studying gene-environment interactions | The UK Biobank project sequenced 500,000 participants' genomes to link genetics to heart disease, diabetes, and mental health outcomes. |
One non-obvious fact: WGS can reveal incidental findings unrelated to the initial reason for testing. A 2021 study in *The New England Journal of Medicine* found that 1 in 10 individuals undergoing WGS for suspected monogenic disease had a secondary finding-such as Lynch syndrome or familial hypercholesterolemia-that altered their long-term care.
Many assume WGS is routinely used in newborn screening. It is not. Most countries still use targeted metabolic and hearing tests. WGS is too expensive and complex for mass screening. The cost of sequencing a human genome dropped from $100 million in 2001 to under $600 in 2023, but interpretation and counseling remain significant barriers.
Another confusion: WGS and ancestry testing. Ancestry services like 23andMe use genotyping arrays-testing only ~700,000 pre-selected SNPs-not full sequencing. They infer ethnicity and traits but miss most variants. WGS provides far greater resolution and accuracy.
I once reviewed a patient's WGS report where a variant in the BRCA1 gene was flagged as "likely pathogenic." The patient had no family history of breast cancer. After re-analysis with updated databases and functional assays, the variant was reclassified as "benign." This highlights that WGS results require expert interpretation-false positives occur due to incomplete knowledge of variant function.
As costs continue to fall, WGS is being integrated into national health systems. The UK's National Health Service launched a pilot program in 2023 to offer WGS to children with unexplained developmental conditions. Early results show diagnostic yield of 30-40%, compared to 10-15% with standard genetic panels.
Privacy remains a concern. A 2022 study in *Nature Genetics* demonstrated that WGS data can be re-identified even when anonymized, especially when combined with public databases. Regulatory frameworks like HIPAA and GDPR apply, but enforcement varies globally.
For individuals considering WGS, understanding the implications is essential. Results may reveal predispositions to late-onset diseases like Alzheimer's or Parkinson's. Some people choose not to receive such information. Counseling before and after testing is recommended by the American College of Medical Genetics and Genomics (ACMG).